232 related articles for article (PubMed ID: 26108357)
1. Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.
Wood JP; Smith AJ; Bowman KJ; Thomas AL; Jones GD
Cancer Med; 2015 Sep; 4(9):1309-21. PubMed ID: 26108357
[TBL] [Abstract][Full Text] [Related]
2. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
Cai X; Cao W; Ding H; Liu T; Zhou X; Wang M; Zhong M; Zhao Z; Xu Q; Wang L
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1579-89. PubMed ID: 23892411
[TBL] [Abstract][Full Text] [Related]
3. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
4. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
5. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
[TBL] [Abstract][Full Text] [Related]
6. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
[TBL] [Abstract][Full Text] [Related]
7. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
8. UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
Liu X; Xu W
Pharmacogenomics; 2014 Jun; 15(9):1171-4. PubMed ID: 25141892
[No Abstract] [Full Text] [Related]
9. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
Fujita K; Kubota Y; Ishida H; Sasaki Y
World J Gastroenterol; 2015 Nov; 21(43):12234-48. PubMed ID: 26604633
[TBL] [Abstract][Full Text] [Related]
10. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ
World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999
[TBL] [Abstract][Full Text] [Related]
11. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
[TBL] [Abstract][Full Text] [Related]
12. The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells.
Kontek R; Nowicka H
Drug Chem Toxicol; 2013 Jul; 36(3):335-42. PubMed ID: 23126525
[TBL] [Abstract][Full Text] [Related]
13. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan in the treatment of colorectal cancer: clinical overview.
Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
[TBL] [Abstract][Full Text] [Related]
16. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Ikeguchi M; Arai Y; Maeta Y; Ashida K; Katano K; Wakatsuki T
Surg Today; 2011 Sep; 41(9):1196-9. PubMed ID: 21874414
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.
Sato T; Hatate K; Ikeda A; Yamanashi T; Ozawa H; Onosato W; Nakamura T; Ihara A; Watanabe M
Expert Opin Pharmacother; 2008 May; 9(7):1223-8. PubMed ID: 18422478
[TBL] [Abstract][Full Text] [Related]
20. A Novel Camptothecin Derivative 3j Inhibits Nsclc Proliferation Via Induction of Cell Cycle Arrest By Topo I-Mediated DNA Damage.
Liu Y; Zhang J; Feng S; Zhao T; Li Z; Wang L; Wang P; Du H; Yuan S; Sun L
Anticancer Agents Med Chem; 2019; 19(3):365-374. PubMed ID: 30523769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
